A centre for pharmaceutical collaboration and research in Amsterdam

Amsterdam UMC will construct a new centre where researchers and the pharmaceutical industry will collaborate on finding treatments for cancer and brain disease. 

ADORE (Amsterdam Oncology and Neuroscience Research) will be the first of its kind in Europe. Amsterdam UMC wants the building to be as innovative and inspiring as the studies that will take place there, believing the fight against cancer and neurodegenerative disease will succeed by combining research efforts and the patient experience. 

An atrium will assist in bringing these two different worlds together and ADORE will also feature a polyclinic for people with MS and Alzheimer’s disease.

ADORE Amsterdam

A conceptual rendering of the ADORE building

Working closely with the Amsterdam UMC Imaging Center 

Located in Zuidas, ADORE will be connected to the Amsterdam UMC Imaging Center, providing access to diagnostic equipment for monitoring the effectiveness of new treatments.

With its dual focus on oncology and neurology, ADORE aims to spur innovations using a ‘bench to bedside’ approach that fuses scientific knowledge with clinical experience. These include new cell therapies, such as immunotherapy for cancer and stem cell therapy for multiple sclerosis. 

The treatment of blood cancer is another project on the horizon. Medicine for this condition is “often very expensive and made for a single person,” says Tuna Mutis, professor of haematology at Amsterdam UMC. “At ADORE, we want to develop therapies that can be more widely applied for a larger group of patients – and the same goes for brain diseases.”

Additionally, ADORE will strive to blur the border between oncology and neurology as well as that between science and business. Companies will be able to join ADORE and gain excess to scientific expertise and high-end equipment. More than 30 businesses have already expressed interest.

20 years of ground-breaking research is guaranteed

The initiators behind ADORE have ensured that the financing is in place so research can continue for at least 20 years. This sense of long-term security is particularly important for scientists whose studies often take many years to complete.
Recognising the Dutch capital’s growing stature as an international centre of medical and pharmaceutical innovation, the City of Amsterdam is also providing a €600,000 subsidy.

Read more business news from around the Amsterdam Area, or find out more about its life sciences and health sector